“Fei Yan No. 1” as a Combined Treatment for COVID-19: An Efficacy and Potential Mechanistic Study
Pharmacology
[키워드] acute respiratory syndrome
Analyzer
Antiviral
Apoptosis
Bioavailability
biological processes
caused
China
Chinese
Clinical efficacy
Clinical treatment
combination therapy
Combined
combined treatment
component
components
Compound
conducted
control group
coronavirus
coronavirus disease
COVID-19
COVID-19 patient
criteria
Cytoscape
database
determine
Fei Yan NO1
Gene ontology
identify
immune response
indicated
Inflammation
KEGG
KEGG pathway
Kyoto
network
network pharmacology
offered
oral
outbreak
parameter
pathway enrichment
Pathways
Patient
Potential
PPI
proportion
protein-protein interaction
public health
regulated
Regulation
Renmin Hospital
representing
Retrospective study
RT-PCR
SARS-CoV-2
SARS-CoV-2 nucleic acid
selected
significantly higher
Symptom
target
targets
TCM
TCMSP
TCMSP database
therapeutic
Topology
treat
Treatment
treatment for COVID-19
were used
[DOI] 10.3389/fphar.2020.581277 PMC 바로가기 [Article Type] Pharmacology
[DOI] 10.3389/fphar.2020.581277 PMC 바로가기 [Article Type] Pharmacology